Licinio Julio, Wong Ma-Li
Center for Pharmacogenomics and Clinical Pharmacology, Neuropsychiatric Institute and David Geffen School of Medicine, University of California, Los Angeles, USA.
Nat Rev Drug Discov. 2005 Feb;4(2):165-71. doi: 10.1038/nrd1634.
Regulatory agencies in the United Kingdom and United States have been critically examining the possible link between suicidality and antidepressant use in children and adults, which has resulted in an FDA directive to the manufacturers of all antidepressant medications to add a 'black box' warning that describes the increased risk of suicidal behaviour in children and adolescents who take antidepressants. A crucial issue in this debate, as we discuss here, is the assessment of the capacity of antidepressants to increase suicidality over and above what is caused by the underlying disorder, major depression, which is itself the principal cause of suicide.
英国和美国的监管机构一直在严格审查儿童和成人自杀倾向与使用抗抑郁药之间可能存在的联系,这导致美国食品药品监督管理局(FDA)向所有抗抑郁药物制造商发出指令,要求添加一个“黑框警告”,描述服用抗抑郁药的儿童和青少年自杀行为风险增加的情况。正如我们在此讨论的,这场辩论中的一个关键问题是评估抗抑郁药在引发自杀倾向方面的能力,这种能力超过了由潜在疾病(重度抑郁症,其本身就是自杀的主要原因)所导致的自杀倾向。